Real-world Secukinumab Outcomes in Canadian HS Patients

Study Summary

The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.

Conditions

Hidradenitis Suppurativa

Interventions / Drugs

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment142 participants

Primary Completion—

Lead SponsorNovartis Pharmaceuticals

Data Retrieved2026-04-11 02:55:49.152735+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.